Nuo Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuo Therapeutics (OTCQB: AURX) reported third-quarter 2026 revenue of $1,866,125, up 80% from the comparable 2025 period. Net loss narrowed to $424,928 from $537,919. Nine-month revenue rose 123% to $4,937,226, while net loss narrowed to $1,320,995 from $1,933,736.
For 2027, Medicare hospital outpatient reimbursement for G0465 increases 7% to approximately $2,257 per treatment; physician fee schedule reimbursement decreases approximately 4% to approximately $1,020. Nursing-home coverage and claims processing expand effective January 1, 2027. Nuo anticipates positive Aurix pricing actions next year.
Cash was $80,941 at September 30, versus $548,946 at December 31, 2025. After quarter-end, Nuo received final loan funding of $325,000, bringing total borrowings under the agreement to $2,000,000. It also received a $250,000 reimbursement fee milestone under its Smith+Nephew distribution agreement.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter revenue increased 80% year over year to $1,866,125.
- Moderate pointThird-quarter gross profit rose to $1,192,791 from $625,375 a year earlier.
- Moderate pointThird-quarter operating loss narrowed approximately $166,000 year over year to $374,432, but widened approximately $208,000 sequentially.
- Moderate pointThird-quarter net loss narrowed to $424,928 from $537,919; loss per share remained $0.01.
- Moderate pointSmith+Nephew distribution agreement delivered a $250,000 reimbursement fee milestone.
- Moderate pointFinal loan funding provided $325,000 after quarter-end.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Medicare hospital outpatient G0465 reimbursement increases 7% to approximately $2,257 per treatment in 2027.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Medicare nursing-home G0465 coverage and claims processing expand effective January 1, 2027.
7 minor points
- Minor pointNine-month revenue increased 123% year over year to $4,937,226.
- Minor pointThird-quarter product revenue increased 5% sequentially; Aurix wound care revenue increased approximately 17%.
- Minor pointNine-month gross profit rose to $3,212,545 from $1,529,587 a year earlier.
- Minor pointNine-month operating loss narrowed to $987,450 from $1,937,311 a year earlier.
- Minor pointNine-month net loss narrowed to $1,320,995; loss per share improved to $0.03 from $0.04.
- Minor point. Forward-looking: it has not happened yet and may not happen.Aurix pricing actions are anticipated to be positive next year, Nuo expects.
- Minor pointHospital-setting Aurix revenue reached its highest quarter ever; its share of wound care sales more than doubled since first-quarter 2026.
Negative
- Moderate pointCash fell to $80,941 at September 30, 2026 from $548,946 at December 31, 2025.
- Moderate pointCurrent liabilities of $2,454,508 exceeded current assets of $1,984,064 at September 30, 2026.
- Moderate pointSecured loan funding established total borrowings under the agreement at $2,000,000 after quarter-end. 3.8% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Medicare physician fee schedule G0465 reimbursement decreases approximately 4% to approximately $1,020 in 2027.
- Moderate pointThird-quarter selling, general and administrative expenses rose to $1,567,223 from $1,165,517 a year earlier.
- Moderate pointNine-month net interest expense increased to $340,447 from $33 a year earlier.
5 minor points
- Minor pointStockholders' deficit widened to $1,848,504 from $956,559 at December 31, 2025.
- Minor pointNine-month selling, general and administrative expenses rose to $4,199,995 from $3,466,898 a year earlier.
- Minor pointComponent supply matters generated more than $100,000 of elevated third-quarter regulatory costs.
- Minor pointThird-quarter net interest expense reached $51,099, versus $409 of net interest income a year earlier.
- Minor pointOutstanding common shares increased to 48,573,894 from 48,179,039 at December 31, 2025, diluting existing holders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Final 2027 Medicare Reimbursement Rulings and Coverage Expansion to New Place of Service Reinforce Growth Outlook
HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the third quarter ended September 30, 2026 and provided an operational and business update.
Third Quarter and First Nine Months 2026 Financial Summary
- Total revenues of approximately
$1.9 million and$4.9 million for the third quarter 2026 and first nine months of 2026, respectively, increased80% and123% , respectively, versus the comparable 2025 periods. - Total product revenues in the third quarter increased
5% sequentially versus the second quarter 2026 with Aurix wound care revenues increasing approximately17% sequentially which is the same average sequential growth rate over the past six quarters for Aurix wound care revenues. - Third quarter net operating loss of approximately
$374,000 improved by approximately$166,000 compared to third quarter 2025 while increasing approximately$208,000 sequentially versus the second quarter. The sequential increase primarily reflected higher stock-based compensation, credit loss provision expense, and more than$100,000 of elevated regulatory costs associated with component supply matters. - Subsequent to quarter end, final funding of
$325,000 was received under the loan agreement with total borrowings established at$2,000,000 .
Operational and Business Update
- Received
$250,000 reimbursement fee milestone pursuant to the 2025 distribution agreement with Smith+Nephew. - Final Medicare OPPS (Outpatient Prospective Payment System) reimbursement ruling recently released for calendar 2027 with the per treatment G0465 national average reimbursement increasing to approximately
$2,257 or7% from 2026 with positive pricing actions for Aurix anticipated next year. - Medicare’s PFS (Physician Fee Schedule) ruling established a G0465 national average reimbursement of approximately
$1,020 in 2027 or a decrease of approximately4% . - Expansion of coverage and processing of G0465 claims for nursing home treatments (Medicare Place of Service 32) effective January 1, 2027 is expected to be positive for future growth.
“As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above,” commented David Jorden, Nuo’s Chief Executive and Financial Officer.
“We have also observed a shift of patients and wound care volumes back to hospital-based settings and enjoyed our highest quarter ever of Aurix revenues in the hospital setting,” continued Mr. Jorden. “Since this year’s first quarter, our HOPD Aurix sales as a percentage of total wound care sales has more than doubled. The economics in hospital settings are strong, and we will continue to pursue and emphasize growth opportunities in this segment. We remain confident that autologous PRP and Aurix in particular are well positioned for continued long term attractive growth.”
“As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth. The funding of the secured notes under the loan agreement in several tranches this year was done with these priorities in mind,” concluded Mr. Jorden.
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Nuo’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include but are not limited to statements regarding Nuo’s anticipated growth opportunities and market positioning, including in the hospital outpatient setting, expectations regarding Medicare reimbursement and coverage changes, including the expansion of coverage to nursing home treatments, and their impact on demand for and pricing of Aurix, anticipated pricing actions, movement toward breakeven operations, and Nuo's ability to strengthen its capital structure. Forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in Nuo’s public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.
Contact:
David Jorden
djorden@nuot.com
| NUO THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 80,941 | $ | 548,946 | ||||
| Accounts receivable, net | 1,410,322 | 561,667 | ||||||
| Inventory, net | 330,134 | 213,761 | ||||||
| Prepaid expenses and other current assets | 162,667 | 55,509 | ||||||
| Total current assets | 1,984,064 | 1,379,883 | ||||||
| Property and equipment, net | 704,903 | 366,315 | ||||||
| Operating lease right of use assets | 41,238 | 99,464 | ||||||
| Total assets | $ | 2,730,205 | $ | 1,845,662 | ||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 756,720 | $ | 436,083 | ||||
| Accrued expenses | 648,177 | 493,792 | ||||||
| Deferred revenue | 380,730 | 300,000 | ||||||
| Current portion of notes payable | 515,625 | - | ||||||
| Current portion of notes payable – related party | 112,500 | - | ||||||
| Current portion of operating lease liabilities | 40,756 | 76,410 | ||||||
| Total current liabilities | 2,454,508 | 1,306,285 | ||||||
| Deferred revenue – long term | 951,826 | 975,000 | ||||||
| Notes payable | 961,875 | 300,000 | ||||||
| Note payable – related party | 210,500 | 200,000 | ||||||
| Non-current portion of operating lease liabilities | - | 20,936 | ||||||
| Total liabilities | 4,578,709 | 2,802,221 | ||||||
| Stockholders' deficit | ||||||||
| Common stock; | 4,857 | 4,818 | ||||||
| Additional paid-in capital | 34,239,796 | 33,810,785 | ||||||
| Accumulated deficit | (36,093,157 | ) | (34,772,162 | ) | ||||
| Total stockholders' deficit | (1,848,504 | ) | (956,559 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 2,730,205 | $ | 1,845,662 | ||||
| NUO THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||
| Three Months ended September 30, 2026 | Three Months ended September 30, 2025 | |||||||
| Revenue | ||||||||
| Product sales | $ | 1,779,563 | $ | 957,096 | ||||
| Distribution fee revenue | 86,562 | 75,000 | ||||||
| Total revenue | 1,866,125 | 1,032,096 | ||||||
| Costs of sales | 673,334 | 406,721 | ||||||
| Gross profit | 1,192,791 | 625,375 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative | 1,567,223 | 1,165,517 | ||||||
| Total operating expenses | 1,567,223 | 1,165,517 | ||||||
| Loss from operations | (374,432 | ) | (540,142 | ) | ||||
| Other income (expense) | ||||||||
| Interest income (expense), net | (51,099 | ) | 409 | |||||
| Other income | 603 | 1,814 | ||||||
| Total other income (expenses) | (50,496 | ) | 2,223 | |||||
| Net loss | $ | (424,928 | ) | $ | (537,919 | ) | ||
| Loss per common share | ||||||||
| Basic and diluted | $ | (0.01 | ) | $ | (0.01 | ) | ||
| Weighted average common shares outstanding | ||||||||
| Basic and diluted | 48,472,374 | 47,539,384 | ||||||
| NUO THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||
| Nine Months ended September 30, 2026 | Nine Months ended September 30, 2025 | |||||||
| Revenue | ||||||||
| Product sales | $ | 4,694,782 | $ | 2,066,679 | ||||
| Distribution fee revenue | 242,444 | 150,000 | ||||||
| Total revenue | 4,937,226 | 2,216,679 | ||||||
| Costs of sales | 1,724,681 | 687,092 | ||||||
| Gross profit | 3,212,545 | 1,529,587 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative | 4,199,995 | 3,466,898 | ||||||
| Total operating expenses | 4,199,995 | 3,466,898 | ||||||
| Loss from operations | (987,450 | ) | (1,937,311 | ) | ||||
| Other income (expense) | ||||||||
| Interest income (expense), net | (340,447 | ) | (33 | ) | ||||
| Other income | 6,902 | 3,608 | ||||||
| Total other income (expenses) | (333,545 | ) | 3,575 | |||||
| Net loss | $ | (1,320,995 | ) | $ | (1,933,736 | ) | ||
| Loss per common share | ||||||||
| Basic and diluted | $ | (0.03 | ) | $ | (0.04 | ) | ||
| Weighted average common shares outstanding | ||||||||
| Basic and diluted | 48,389,216 | 47,062,186 | ||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Nuo Therapeutics' third-quarter 2026 financial results?
Nuo reported $1,866,125 in revenue and a $424,928 net loss for the quarter ended September 30, 2026. Revenue increased 80% from the comparable 2025 period. Net loss narrowed from $537,919, while basic and diluted loss per share remained $0.01.
How will 2027 Medicare reimbursement change for Nuo Therapeutics' Aurix treatments?
The G0465 national average hospital outpatient reimbursement increases 7% to approximately $2,257 per treatment, while physician fee schedule reimbursement decreases approximately 4% to approximately $1,020. Coverage and claims processing for nursing-home treatments under Medicare Place of Service 32 expand effective January 1, 2027.
What business priorities did Nuo Therapeutics identify in its third-quarter 2026 update?
Nuo is prioritizing reaching the revenue level required for operational breakeven and assessing opportunities to strengthen its capital structure for its next growth stage. The company also plans to continue pursuing growth opportunities in hospital-based settings.